In conclusion, this study provides the first evidence to support a better outcome for p16-positive HNSCC patients when treated with RT combined with EGFR inhibitors vs. RT combined with traditional cisplatin-based CT. Here, CDKN2A is linked to head and neck squamous cell carcinoma.